Neuphoria Therapeutics Inc. (NEUP) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2026, Neuphoria Therapeutics reported revenue of $1.2M, down 92.5% from $15.6M the year before. Net income was -$13.5M (a -1145.7% net margin), or -$3.06 per diluted share. Operating margin was -1401.1%. Operating activities generated -$12.4M of cash, leaving -$12.4M of free cash flow. At fiscal year end, Neuphoria Therapeutics held $28.7M in total assets against $4.1M in total liabilities, including $19.9M of cash and equivalents.
Open the full interactive Neuphoria Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Neuphoria Therapeutics Key Stats
| Share Price | $3.39 |
|---|---|
| Market Cap | $14.9M |
| Revenue YoY Growth | -92.5% |
| 52-Week Range | $3.30 – $17.24 |
| Shares Outstanding | 4.4 million (basic, 2026 Q4) |
Neuphoria Therapeutics Income Statement
| FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|
| Revenue | $0 | $15.6M | $1.2M |
| Operating Income | -$17.9M | -$1.1M | -$16.5M |
| Pre-Tax Income | -$15.6M | -$837,998 | -$13.6M |
| Income Tax | -$87,320 | -$468,366 | -$139,173 |
| Net Income | -$15.5M | -$369,632 | -$13.5M |
| Diluted EPS | -$0.12 | -$0.23 | -$3.06 |
Neuphoria Therapeutics Quarterly Results
| 2026 Q1 | 2026 Q2 | 2026 Q3 | 2026 Q4 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1.2M |
| Net Income | -$9.9M | $1.9M | -$505,063 | -$4.9M |
| Diluted EPS | -$4.41 | -$0.77 | -$0.09 | -$1.12 |
Neuphoria Therapeutics Balance Sheet
| FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|
| Cash & Equivalents | $12.6M | $14.2M | $19.9M |
| Current Assets | $13.2M | $15.0M | $21.1M |
| Total Assets | $27.6M | $28.6M | $28.7M |
| Current Liabilities | $3.8M | $4.2M | $756,581 |
| Total Liabilities | $10.2M | $9.6M | $4.1M |
| Shareholders' Equity | $17.5M | $19.0M | $24.6M |
Neuphoria Therapeutics Cash Flow Statement
| FY 2024 | FY 2025 | FY 2026 | |
|---|---|---|---|
| Cash From Operations | -$14.7M | $77,229 | -$12.4M |
| Cash From Financing | $15.1M | $1.5M | $17.9M |
| Free Cash Flow | -$14.7M | $100,000 | -$12.4M |
Figures from Neuphoria Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Neuphoria Therapeutics financials page for every line item.
Neuphoria Therapeutics Company Profile
| Ticker | NEUP |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Burlington, Massachusetts |
| Fiscal Year End | June 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001191070 |
Frequently Asked Questions
What was Neuphoria Therapeutics' revenue in fiscal 2026?
Neuphoria Therapeutics (NEUP) reported revenue of $1.2M for fiscal 2026.
What is Neuphoria Therapeutics' annual revenue history?
Neuphoria Therapeutics' annual revenue by fiscal year: 2024: $0; 2025: $15.6M; 2026: $1.2M.
What was Neuphoria Therapeutics' net income in fiscal 2026?
Neuphoria Therapeutics reported net income of -$13.5M for fiscal 2026.
What was Neuphoria Therapeutics' earnings per share (EPS) in fiscal 2026?
Neuphoria Therapeutics' diluted EPS was -$3.06 for fiscal 2026 (adjusted for any later stock splits).
How much free cash flow did Neuphoria Therapeutics generate in fiscal 2026?
Neuphoria Therapeutics generated -$12.4M of free cash flow in fiscal 2026.
What was Neuphoria Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q4), Neuphoria Therapeutics reported revenue of $1.2M.
How many shares of Neuphoria Therapeutics are outstanding?
Neuphoria Therapeutics reported a weighted average of 4.4 million basic shares outstanding in 2026 Q4.
What is Neuphoria Therapeutics' market cap?
Based on its latest closing price, Neuphoria Therapeutics (NEUP) has a market capitalization of about $14.9M.
When does Neuphoria Therapeutics' fiscal year end?
Neuphoria Therapeutics' fiscal year end, as registered with the SEC, is June 30.
Where is Neuphoria Therapeutics headquartered?
Neuphoria Therapeutics lists its business address in Burlington, Massachusetts in its SEC filings.